Imperial College London
Alternate

ProfessorMatthewPickering

Faculty of Medicine, Department of Immunology and Inflammation

Centre Director, Professor of Rheumatology
 
 
 
//

Contact

 

matthew.pickering Website

 
 
//

Assistant

 

Miss Claudia Rocchi +44 (0)20 3313 2315

 
//

Location

 

9N12Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Medjeral-Thomas:2021:oxfimm/iqab014,
author = {Medjeral-Thomas, N and Troldborg, A and Hansen, A and Pihl, R and Clarke, C and Peters, J and Thomas, D and Willicombe, M and Palarasah, Y and Botto, M and Pickering, M and Thiel, S},
doi = {oxfimm/iqab014},
journal = {Oxford Open Immunology},
title = {Protease inhibitor plasma concentrations associate with COVID-19 infection},
url = {http://dx.doi.org/10.1093/oxfimm/iqab014},
volume = {2},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Protease inhibitors influence a range of innate immunity and inflammatory pathways. We quantified plasma concentrations of key anti-inflammatory protease inhibitors in chronic haemodialysis patients with COVID-19. The samples were collected early in the disease course to determine whether plasma protease inhibitor levels associated with the presence and severity of COVID-19. We used antibody-based immunoassays to measure plasma concentrations of C1 esterase inhibitor (C1-INH), alpha2-macroglobulin (α2M), antithrombin, and inter-alpha-inhibitor heavy chain 4 (ITIH4) in 100 serial samples from 27 haemodialysis patients with COVID-19. ITIH4 was tested in two assays, one measuring intact ITIH4 and another also detecting any fragmented ITIH4 (total ITIH4). Control cohorts were 32 haemodialysis patients without COVID-19 and 32 healthy controls. We compared protease inhibitor concentration based on current and future COVID-19 severity and with CRP. Results were adjusted for repeated measures and multiple comparisons. Analysis of all available samples demonstrated lower plasma C1-INH and α2M and higher total ITIH4 in COVID-19 compared to dialysis controls. These differences were also seen in the first sample collected after COVID-19 diagnosis, a median of four days from diagnostic swab. Plasma ITIH4 levels were higher in severe than non-severe COVID-19. Serum CRP correlated positively with plasma levels of antithrombin, intact ITIH4, and total ITIH4. In conclusion, plasma protease inhibitor concentrations are altered in COVID-19.
AU  - Medjeral-Thomas,N
AU  - Troldborg,A
AU  - Hansen,A
AU  - Pihl,R
AU  - Clarke,C
AU  - Peters,J
AU  - Thomas,D
AU  - Willicombe,M
AU  - Palarasah,Y
AU  - Botto,M
AU  - Pickering,M
AU  - Thiel,S
DO  - oxfimm/iqab014
PY  - 2021///
SN  - 2633-6960
TI  - Protease inhibitor plasma concentrations associate with COVID-19 infection
T2  - Oxford Open Immunology
UR  - http://dx.doi.org/10.1093/oxfimm/iqab014
UR  - http://hdl.handle.net/10044/1/90186
VL  - 2
ER  -
Download